The anti-CD4CAR LVs in the current study recognized specifically CD8 as target receptor and allowed the generation of CD4-directed CAR CD8 T cells in vivo, which eliminated CD4 + malignant T cells in a primary murine AITL lymphoma. This evidence concerns the gene CD8A and angioimmunoblastic T-cell lymphoma.